Juebin Huang, MD
Neurology · Jackson, MSNPI 1477851996
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,480 of the $20,222 with a category attached, or 66.7%. 36 manufacturers reported payments, led by Merck at 56.8% of the total. Reporting peaked in 2020 at $5,056 and has fallen 66.6% since, to $1,690 in 2025.
Across 264 payments — averaging $76.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$11K
- Acadia Pharmaceuticals Inc$3K
- Amneal Pharmaceuticals LLC$2K
- Teva Pharmaceuticals USA, Inc.$824
- Neurocrine Biosciences, Inc.$267
- Kyowa Kirin, Inc.$260
- plus $3K from 30 others
Across 28 payments — averaging $7538.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$201K
- Eli Lilly$10K
What the payments were for
- Consulting fees$13,48067%
- Speaking & faculty fees$2,27111%
- Food & beverage$4,15321%
- Education$3172%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 14 | $11,480 |
| Acadia Pharmaceuticals Inc | 33 | $2,539 |
| Amneal Pharmaceuticals LLC | 5 | $2,278 |
| Teva Pharmaceuticals USA, Inc. | 35 | $824 |
| Neurocrine Biosciences, Inc. | 16 | $267 |
| Kyowa Kirin, Inc. | 19 | $260 |
| Sunovion Pharmaceuticals Inc. | 14 | $209 |
| Supernus Pharmaceuticals, Inc. | 10 | $203 |
| Eisai Inc. | 14 | $186 |
| Amgen | 10 | $186 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $168 |
| Avanir Pharmaceuticals, Inc. | 11 | $163 |
| AstraZeneca(2 entities) | 4 | $162 |
| UCB, Inc. | 10 | $160 |
| MDD US Operations, LLC | 6 | $133 |
| Sanofi | 8 | $128 |
| Argenx US, Inc. | 2 | $125 |
| EMD Serono, Inc. | 7 | $106 |
| Lundbeck LLC | 3 | $104 |
| GE HealthCare | 5 | $78 |
| Greenwich Biosciences, Inc. | 3 | $67 |
| Novartis | 3 | $63 |
| Acorda Therapeutics, Inc | 3 | $49 |
| Biohaven Pharmaceuticals, Inc. | 3 | $37 |
| Upsher-smith Laboratories LLC | 3 | $37 |
| Biogen | 2 | $30 |
| AbbVie | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| TG Therapeutics, Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $16 |
| SK Life Science, Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Assertio Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,222 in reported general payments places this provider in the 80th percentile of 111 neurology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 66 | $601,798 |
| NuplazidPimavanserin Tartrate | 34 | $171,501 |
| Austedo XrDeutetrabenazine | 14 | $73,684 |
| InbrijaLevodopa | 18 | $45,623 |
| RytaryCarbidopa/Levodopa | 13 | $24,979 |
| NeuproRotigotine | 12 | $13,085 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 381 | $9,731 |
| Rivastigmine | 31 | $7,652 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 105 | $3,579 |
| Lacosamide | 22 | $3,488 |
| AmantadineAmantadine Hcl | 89 | $2,633 |
| Memantine Hcl | 121 | $2,238 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 13 | $2,198 |
| Donepezil Hcl | 262 | $1,816 |
| Ropinirole Hcl | 70 | $1,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $824 | $675,48280 claims |
| Acadia Pharmaceuticals IncNuplazid | $2,539 | $171,50134 claims |
| Acorda Therapeutics, IncInbrija | $49 | $45,62318 claims |
| Amneal Pharmaceuticals LLCRytary | $2,278 | $24,97913 claims |
| UCB, Inc.Neupro | $160 | $13,08512 claims |
| Upsher-smith Laboratories LLCTopiramate | $37 | $87427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 111 neurology providers in Mississippi.
Other neurology in Jackson
- Ruth FredericksJackson$943K
- Wendell HelvestonJackson$883K
- Rajesh SharmaJackson$152K
- Patrick WeldonJackson$85K
- Riichi OtaJackson$53K
- Mitchell MyersJackson$43K
- Tiffany ScarffJackson$29K
- Derek LetortJackson$25K
- Shreyas GangadharaJackson$20K
- David McHenryJackson$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.